The latest news from academia, regulators
research labs and other things of interest
Posted: April 1, 2008
Living Cell Technologies Showcases Proprietary Nanobiocapsules at NZBio 2008
(Nanowerk News) Living Cell Technologies Limited (ASX: LCT) (PINKSHEETS: LVCLY) today announced that Dr. Paul Tan, LCT CEO and Dr. Anil K. Anal, LCT Material Scientist, presented some data at a session on nanotechnology at the NZBio 2008 Conference in Auckland, New Zealand. Their presentation showcased the company's proprietary nanobiocapsules which allow encapsulated pig insulin producing cells, DiabeCell®, to be implanted without the use of toxic immune suppressive drugs.
On March 31, the Company reported positive early preliminary data from an on-going Phase I/IIa clinical trial which shows that following implant into patients with insulin dependent diabetes, the encapsulated porcine pancreatic islets remain functioning for at least 6 months and beneficial effects were greater than expected.
Dr. Paul Tan said, "The positive clinical effects indicate that our technology has succeeded in placing cells into gel capsules which allow oxygen and nutrients to pass inward and insulin to diffuse outward while preventing immune agents from destroying the cells. This was achieved due to the highly selective materials used layer by layer to form the capsule wall with pores of the appropriate size and nanoscale."
Scientific American describes Nanotechnology as technology which "broadly applies to control of materials and components only a few billionths of a meter in size." LCT's nanobiocapsules are the result of controlled chemical reactions that produce molecular structures with pores less than 50 nanometers in diameter as seen by atomic force microscopy and confocal laser scanning microscopy.
About Living Cell Technologies: www.lctglobal.com
Living Cell is developing cell-based products to treat life threatening human diseases. The Company owns a bio-certified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. For patients having type 1 diabetes, the Company implants micro-encapsulated islet cells so that near-normal blood glucose levels may be achieved without the need for administration of insulin or at significantly reduced levels. The company entered clinical trials for its diabetes product in 2007. The Company is developing treatments for Huntington's disease and other neurological disorders that involve implantation of micro-encapsulated choroid plexus cells to deliver beneficial proteins and neurotrophic factors to the brain. Living Cell's technology has the potential for allowing healthy living cells to be injected into patients to replace or repair damaged tissue without requiring the use of immunosuppressive drugs to prevent rejection. Living Cell also is developing medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes. The changes in this paragraph reflect that the company only is developing or might develop certain products, and is not manufacturing or selling any products other than DiabeCell.